Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

Purpose: To evaluate the toxicity, efficacy, and pharmacokinetics of doceta xel when combined with oral estramustine and dexamethasone in a phase I stu dy in patients with progressive metastatic androgen-independent prostate ca ncer. Patients and Methods: Thirty-four men were stratified into minimally pretre ated (MPT) and extensively pretreated (EPT) groups. Estramustine 280 mg PO tid was administered 1 hour before or 2 hours after meals on days I through 5, with escalated doses of docetaxel from 40 to 80 mg/m(2) on day 2. Treat ment was repeated every 21 days. Results: Thirty-four patients were assessable for toxicity and 33 for respo nse. In the MPT patients, dose-limiting myelosuppression was reached at 80 mg/m2, with six patients experiencing grade 3/4 granulocytopenia. In EPT pa tients, escalation above 70 mg/m(2) was not attempted. Fourteen MPT (70%) a nd six EPT (50%) patients had a greater than or equal to 50% decline in ser um PSA on two consecutive measurements taken at least 2 weeks apart. The ov erall 50% PSA response rate was 63% (95% confidence interval [CI], 28% ta 8 1%). Of the 18 patients with bidimensionally measurable disease, five (28%; 95% Cl, 11% ta 54%) achieved a partial response. At the time of entry onto the study 15 patients required narcotic analgesics for bone paint after tr eatment, eight (53%) discontinued their pain medications. The area under th e curve for docetaxel increased linearly from 40 to 70 mg/m(2). At 80 mg/m( 2), the measured area under the curve was 8.37 (standard deviation, 0.724), which was significantly higher than the previously reported values. Conclusion: The recommended phase II dose of docetaxel combined with estram ustine is 70 mg/m(2) in MPT patients and 60 mg/m(2) in EPT patients. This c ombination is active in men with androgen-independent prostate cancer. (C) 1999 by American Society of Clinical Oncology.